Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ANPCYNASDAQ:BIAFWOTCMKTS:EPGNYOTCMKTS:IZOZF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANPCYANGLEC$0.99C$1.25C$0.74▼C$3.35N/AN/A1,186 shs52 shsBIAFWbioAffinity Technologies$0.15-35.7%$0.27$0.12▼$2.90N/AN/A8,406 shs147 shsEPGNYEpigenomics$2.39$2.39$2.01▼$2.39N/AN/A100 shsN/AIZOZFIzotropic$0.16-16.6%$0.22$0.02▼$0.33N/AN/A43,026 shs1,200 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANPCYANGLE0.00%0.00%-17.40%-33.03%-47.56%BIAFWbioAffinity Technologies-11.70%-13.71%-30.73%-50.31%-66.44%EPGNYEpigenomics0.00%0.00%0.00%0.00%0.00%IZOZFIzotropic0.00%-13.64%-14.61%+11.76%+111.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANPCYANGLEN/AN/AN/AN/AN/AN/AN/AN/ABIAFWbioAffinity TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AEPGNYEpigenomicsN/AN/AN/AN/AN/AN/AN/AN/AIZOZFIzotropicN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANPCYANGLE 0.00N/AN/AN/ABIAFWbioAffinity Technologies 0.00N/AN/AN/AEPGNYEpigenomics 0.00N/AN/AN/AIZOZFIzotropic 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANPCYANGLEN/AN/AN/AN/AN/AN/ABIAFWbioAffinity Technologies$9.36MN/AN/AN/AN/AN/AEPGNYEpigenomicsN/AN/AN/AN/AN/AN/AIZOZFIzotropicN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANPCYANGLEN/A-C$0.48N/A∞N/AN/AN/AN/AN/ABIAFWbioAffinity TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AEPGNYEpigenomicsN/A-$3.05N/A∞N/AN/AN/AN/AN/AIZOZFIzotropicN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANPCYANGLEN/AN/AN/AN/AN/ABIAFWbioAffinity TechnologiesN/AN/AN/AN/AN/AEPGNYEpigenomicsN/AN/AN/AN/AN/AIZOZFIzotropicN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANPCYANGLEN/ABIAFWbioAffinity TechnologiesN/AEPGNYEpigenomicsN/AIZOZFIzotropicN/AInsider OwnershipCompanyInsider OwnershipANPCYANGLEN/ABIAFWbioAffinity TechnologiesN/AEPGNYEpigenomicsN/AIZOZFIzotropicN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANPCYANGLE173N/AN/ANot OptionableBIAFWbioAffinity Technologies10N/AN/ANot OptionableEPGNYEpigenomics32N/AN/ANot OptionableIZOZFIzotropicN/AN/AN/ANot OptionableIZOZF, ANPCY, BIAFW, and EPGNY HeadlinesRecent News About These CompaniesIzotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary LenderApril 2, 2025 | newsfilecorp.comIzotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening IndicationMarch 25, 2025 | newsfilecorp.comIzotropic to Present at Investor Conference March 13thMarch 10, 2025 | newsfilecorp.comFDA Sets Meeting Date with IzotropicFebruary 19, 2025 | newsfilecorp.comIzotropic Closes Non-Brokered Private PlacementFebruary 14, 2025 | newsfilecorp.comIzotropic Announces Non-Brokered Private PlacementFebruary 7, 2025 | newsfilecorp.comIzotropic Reschedules Investor Conference Presentation to March 13thFebruary 5, 2025 | newsfilecorp.comIzotropic to Present at Investor Conference February 6thFebruary 3, 2025 | globenewswire.comIzotropic to Present at Investor Conference February 6thFebruary 3, 2025 | newsfilecorp.comIzotropic Announces Timelines and Milestones to IzoView Product LaunchJanuary 29, 2025 | newsfilecorp.comIzotropic Featured in Announcement of Research and Markets' U.S. Breast Cancer Analysis and ForecastJanuary 17, 2025 | newsfilecorp.comIzotropic Announces Team Leading Clinical Study Design and FDA Regulatory SubmissionsJanuary 15, 2025 | newsfilecorp.comFiling Pre-Submission with U.S. FDA Sends Shares Of This Biotech HigherJanuary 10, 2025 | msn.comIzotropic Files Pre-Submission with U.S. FDA for Breast Cancer ScreeningJanuary 9, 2025 | newsfilecorp.comIzotropic Provides Update on Annual General Meeting Materials and Voting ProceduresDecember 4, 2024 | newsfilecorp.comIzotropic to launch Izoview for breast cancer diagnosticsAugust 24, 2024 | msn.comIzotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EUAugust 23, 2024 | newsfilecorp.comDanaher AktieAugust 6, 2024 | finanzen100.deIzotropic Corporation Announces Closing of First Tranche of Non-Brokered Private PlacementJune 14, 2024 | newsfilecorp.comIzotropic Corporation Announces Non-Brokered Private PlacementJune 6, 2024 | newsfilecorp.comMedia Sentiment Over TimeIZOZF, ANPCY, BIAFW, and EPGNY Company DescriptionsANGLE OTCMKTS:ANPCYC$0.99 0.00 (0.00%) As of 04/28/2025ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.bioAffinity Technologies NASDAQ:BIAFW$0.15 -0.08 (-35.68%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.Epigenomics OTCMKTS:EPGNY$2.39 0.00 (0.00%) As of 04/6/2023Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.Izotropic OTCMKTS:IZOZF$0.16 -0.03 (-16.63%) As of 12:30 PM EasternIzotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses. Izotropic Corporation was incorporated in 2016 and is headquartered in Surrey, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
